Back HIV/AIDS HIV/AIDS Topics HIV Treatment

European AIDS Conference Opens this Week in Brussels

The 14th European AIDS Conference, the biennial meeting of the European AIDS Clinical Society (EACS), takes place this week in Brussels. EACS 2013 will immediately follow the 15th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV, and will hold joint sessions on the hepatitis C treatment revolution and managing complications such as cardiovascular disease and osteoporosis.

alt

Read more:

IDWeek 2013: Complera Works Well Regardless of Viral Load or CD4 Count, Improves Lipid Levels

The single-tablet regimen Complera (rilpivirine/tenofovir/emtricitabine) worked as well as Atripla (efavirenz/tenofovir/emtricitabine) for treatment-naive people across a range of viral load and CD4 T-cell levels, researchers reported at the Second IDWeek conference last week in San Francisco. Another study found that switching from a boosted protease inhibitor to Complera lowered cholesterol and triglyceride levels.

alt

Read more:

IDWeek 2013: Monitoring Every 6 Months Is Adequate For People with Stable HIV Suppression

People with HIV who have their viral load and CD4 T-cell count monitored every 6 months were no more likely to experience virological failure or to change their antiretroviral regimens than those monitored every 4 months, researchers reported at the Second IDWeek meeting last week in San Francisco.

alt

Read more:

IDWeek 2103: The Past, Present, and Future of HIV Treatment

More that 25 years after approval of the first antiretroviral drug -- AZT in 1987 -- several presenters at the 2nd IDWeek meeting last week in San Franciscodiscussed the history, state-of-the-art, and future of HIV treatment. Modern antiretroviral therapy (ART) has kep countless people alive, but researchers and people with HIV are now looking toward biomedical prevention and ultimately a cure.

alt

Read more:

IDWeek 2013: Does Efavirenz Use Raise the Risk of Suicide Among People with HIV?

Suicidal thoughts, attempted suicide, and death by suicide were more than twice as common among people with HIV who started treatment with efavirenz, but the overall risk was quite low, according to a combined analysis of 4 ACTG trials with more than 5000 participants presented at the Second IDWeek meeting last week in San Francisco.

alt

Read more:

Coverage of IDWeek 2013

HIVandHepatitis.com coverage of the Second ID Week, October 2-6, in San Francisco.

Conference highlights include antiretroviral therapy strategies, investigational agents for HIV and hepatitis C, management of HIV-related complications, biomedical HIV prevention, and HIV cure research.

Full listing by topic

10/8/13

alt

 

 

IDWeek 2013: People with HIV Have Higher Risk of Death after Myocardial Infarction

People with HIV had higher mortality than HIV negative individuals of the same age after hospitalization for acute coronary syndrome, but the excess risk disappeared for people on antiretroviral therapy (ART) with high CD4 T-cell counts, researchers reported last week at the Second IDWeek conference in San Francisco.

alt

Read more: